{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:07:02Z","timestamp":1792897622243,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41591-024-03419-3","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:03:30Z","timestamp":1736226210000},"page":"639-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Yeming","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoru","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangqi","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganzhu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6991-0350","authenticated-orcid":false,"given":"Bin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"3419_CR1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.meegid.2018.08.007","volume":"65","author":"J-E Park","year":"2018","unstructured":"Park, J.-E. & Ryu, Y. Transmissibility and severity of influenza virus by subtype. Infect. Genet. Evol. 65, 288\u2013292 (2018).","journal-title":"Infect. Genet. Evol."},{"key":"3419_CR2","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano, A. D. et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391, 1285\u20131300 (2018).","journal-title":"Lancet"},{"key":"3419_CR3","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1016\/S2468-2667(19)30163-X","volume":"4","author":"L Li","year":"2019","unstructured":"Li, L. et al. Influenza-associated excess respiratory mortality in China, 2010\u201315: a population-based study. Lancet Public Health 4, e473\u2013e481 (2019).","journal-title":"Lancet Public Health"},{"key":"3419_CR4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","volume":"12","author":"AC Hurt","year":"2012","unstructured":"Hurt, A. C. et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect. Dis. 12, 240\u2013248 (2012).","journal-title":"Lancet Infect. Dis."},{"key":"3419_CR5","doi-asserted-by":"publisher","first-page":"4929","DOI":"10.3390\/v7092850","volume":"7","author":"TC Li","year":"2015","unstructured":"Li, T. C., Chan, M. C. W. & Lee, N. Clinical implications of antiviral resistance in influenza. Viruses 7, 4929\u20134944 (2015).","journal-title":"Viruses"},{"key":"3419_CR6","doi-asserted-by":"publisher","first-page":"a038463","DOI":"10.1101\/cshperspect.a038463","volume":"11","author":"JH Beigel","year":"2021","unstructured":"Beigel, J. H., & Hayden, F. G. Influenza therapeutics in clinical practice\u2014challenges and recent advances. Cold Spring Harb. Perspect. Med. 11, a038463 (2021).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"3419_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature14008","volume":"516","author":"A Pflug","year":"2014","unstructured":"Pflug, A., Guilligay, D., Reich, S. & Cusack, S. Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516, 355\u2013360 (2014).","journal-title":"Nature"},{"key":"3419_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nature14009","volume":"516","author":"S Reich","year":"2014","unstructured":"Reich, S. et al. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 516, 361\u2013366 (2014).","journal-title":"Nature"},{"key":"3419_CR9","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/infdis\/jiac135","volume":"226","author":"FG Hayden","year":"2022","unstructured":"Hayden, F. G. et al. Favipiravir treatment of uncomplicated influenza in adults: results of two phase 3, randomized, double-blind, placebo-controlled trials. J. Infect. Dis. 226, 1790\u20131799 (2022).","journal-title":"J. Infect. Dis."},{"key":"3419_CR10","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1021\/jm5007275","volume":"57","author":"MP Clark","year":"2014","unstructured":"Clark, M. P. et al. Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2. J. Med. Chem. 57, 6668\u20136678 (2014).","journal-title":"J. Med. Chem."},{"key":"3419_CR11","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","volume":"219","author":"RW Finberg","year":"2019","unstructured":"Finberg, R. W. et al. Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial. J. Infect. Dis. 219, 1026\u20131034 (2019).","journal-title":"J. Infect. Dis."},{"key":"3419_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S1473-3099(23)00743-0","volume":"24","author":"Z Yang","year":"2024","unstructured":"Yang, Z. et al. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 24, 535\u2013545 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3419_CR13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","volume":"379","author":"FG Hayden","year":"2018","unstructured":"Hayden, F. G. et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N. Engl. J. Med. 379, 913\u2013923 (2018).","journal-title":"N. Engl. J. Med."},{"key":"3419_CR14","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","volume":"20","author":"MG Ison","year":"2020","unstructured":"Ison, M. G. et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect. Dis. 20, 1204\u20131214 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"3419_CR15","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1097\/INF.0000000000002747","volume":"39","author":"J Baker","year":"2020","unstructured":"Baker, J. et al. Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2). Pediatr. Infect. Dis. J. 39, 700\u2013705 (2020).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"3419_CR16","first-page":"346","volume":"221","author":"T Uehara","year":"2020","unstructured":"Uehara, T. et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J. Infect. Dis. 221, 346\u2013355 (2020).","journal-title":"J. Infect. Dis."},{"key":"3419_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/cid\/ciz908","volume":"71","author":"N Hirotsu","year":"2020","unstructured":"Hirotsu, N. et al. Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin. Infect. Dis. 71, 971\u2013981 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"3419_CR18","doi-asserted-by":"publisher","first-page":"104828","DOI":"10.1016\/j.antiviral.2020.104828","volume":"180","author":"E Takashita","year":"2020","unstructured":"Takashita, E. et al. Influenza A(H1N1)pdm09 virus exhibiting reduced susceptibility to baloxavir due to a PA E23K substitution detected from a child without baloxavir treatment. Antiviral Res. 180, 104828 (2020).","journal-title":"Antiviral Res."},{"key":"3419_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/jac\/dky462","volume":"74","author":"K Fukao","year":"2019","unstructured":"Fukao, K. et al. Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J. Antimicrob. Chemother. 74, 654\u2013662 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"3419_CR20","doi-asserted-by":"publisher","first-page":"105126","DOI":"10.1016\/j.antiviral.2021.105126","volume":"193","author":"J-H Park","year":"2021","unstructured":"Park, J.-H. et al. Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model. Antiviral Res. 193, 105126 (2021).","journal-title":"Antiviral Res."},{"key":"3419_CR21","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","volume":"221","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J. Infect. Dis. 221, 1688\u20131698 (2020).","journal-title":"J. Infect. Dis."},{"key":"3419_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","volume":"355","author":"KG Nicholson","year":"2000","unstructured":"Nicholson, K. G. et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355, 1845\u20131850 (2000).","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1038\/s41591-025-03541-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03419-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03419-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03419-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:03:38Z","timestamp":1739901818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03419-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3419"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03419-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"assertion":[{"value":"2 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03541-w","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03541-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The clinical trial titled \u2018Severe Influenza Trial of Arbidol\u2019 (ClinicalTrials.gov registration:\n                      \n                      ) has received support from Shijiazhuang No.4 Pharmaceutical.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}